The U.S. Food and Drug Administration yesterday approved a new oral medication for rheumatoid arthritis, or RA. Tofacitinib, brand name Xeljanz (ZEL'jans) , is for patients with moderate to severe rheumatoid arthritis who do not respond well to methotrexate, a disease-modifying antirheumatic drug, or DMARD.